Table 3.
Mean (±SD) Pharmacokinetic Parameters of Sumatriptan Following Single‐Dose Oral Administration of Sumatriptan Alone or in Combination With Ubrogepant in Healthy Adult Participants
| PK Parameter, Mean (SD) | Sumatriptan 100 mg (n = 29) | Ubrogepant 100 mg + Sumatriptan 100 mg (n = 29) |
|---|---|---|
| C max, ng/mL | 59.13 (30.99) | 53.51 (17.73) |
| AUC0‐ t, ng•h/mL | 270.18 (105.21) | 261.16 (85.29) |
| AUC0‐∞, ng•h/mL | 279.78 (106.66) | 273.85 (87.00) |
| t max, hours† | 1.00 (0.50‐5.00) | 3.00 (0.50‐6.00) |
| t ½, hours‡ | 4.08 (2.57) | 5.09 (4.59) |
| Vz/F, L | 2377.90 (1609.15) | 2952.18 (3096.92) |
| CL/F, L/h | 416.54 (190.28) | 408.43 (154.66) |
AUC0‐∞ = area under the plasma drug concentration vs time curve from time 0 to infinity; AUC0‐ t = area under the plasma drug concentration vs time curve from time 0 to time t; CL/F = apparent total clearance of the drug from plasma after oral administration; Cmax = maximum plasma drug concentration; t ½ = mean apparent terminal elimination half‐life; t max = time to maximum plasma drug concentration; Vz/F = apparent volume of distribution during terminal phase after non‐intravenous administration.
†
Median (range).
‡
Mean apparent terminal elimination half‐life.